Land: Israel
Språk: engelsk
Kilde: Ministry of Health
NIFEDIPINE
CTS CHEMICAL INDUSTRIES LTD, ISRAEL
C08CA05
TABLETS PROLONGED RELEASE
NIFEDIPINE 60 MG
PER OS
Required
VALPHARMA S.P.A., REPUBLIC OF SAN MARINO
NIFEDIPINE
NIFEDIPINE
Chronic stable angina, hypertension.
2017-12-31
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS )PREPARATIONS( – 1986 The medicine is dispensed with a doctor’s prescription only NIFEDILONG 30 MG PROLONGED RELEASE TABLETS. NIFEDILONG 60 MG PROLONGED RELEASE TABLETS. Each prolonged release tablet of Nifedilong 30 mg contains: Nifedipine 30 mg Each prolonged release tablet of Nifedilong 60 mg contains: Nifedipine 60 mg Inactive ingredients in the medicine – see section 6. READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have any other questions, refer to the doctor or the pharmacist. This medicine has been prescribed for treatment of your illness. Do not pass it on to others. It may harm them even if it seems to you that their medical condition is similar. This medicine is not intended for children and adolescents under the age of 18. 1. WHAT IS THE MEDICINE INTENDED FOR? The medicine is intended for treatment of chronic and stable angina, and for treatment of hypertension. THERAPEUTIC CLASS: Calcium channel blockers. 2. BEFORE USING THE MEDICINE: DO NOT USE THIS MEDICINE IF: You had a heart attack in the past month. You previously collapsed due to a cardiac problem )cardiogenic shock(, resulting in symptoms of respiratory arrest, pallor, dry mouth and cold sweat. You had esophageal obstruction. You had surgery for removal of the colon )colectomy( and formation of a pouch from a loop of the small intestine, which is attached to the stomach wall and can be emptied by the patient )Kock Pouch(, Stoma. Your blood pressure keeps rising despite treatment with the medicine )malignant hypertension(. Sensitivity to one of the medicine’s ingredients )specified in section 6( is known, or to a similar medicine that belongs to the dihydropyridine group. There is hypersensitivity to Nifedipine. Do not use the medicine for treatment of acute angina or an unstable angina. You are suffering from liver diseases. You are suffering from aortic stenosis. You are suffering from i read_full_document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nifedilong 30 mg prolonged-release tablets Nifedilong 60 mg prolonged-release tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 30 or 60 mg nifedipine, respectively. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged-release film-coated tablet. Round biconvex tablets with a pale red colour. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS For the treatment of chronic stable angina and hypertension. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Posology_ _Adults:_ Dosage must be adjusted according to each patient's needs. Therapy for either hypertension or angina should be initiated with 30 or 60 mg once daily. _Nifedilong Prolonged Release tablets_ should be swallowed whole and should not be bitten or divided. In general, titration should proceed over at 7-14 day period so that the physician can fully assess the response to each dose level and monitor blood pressure before proceeding to higher doses. Since steady- state plasma levels are achieved on the second day of dosing, if symptoms so warrant, titration may proceed more rapidly provided the patient is assessed frequently. Titration to doses above 120 mg are not recommended. _A_ _ _ _Switch over from Nifedipine capsules to Nifedilong_ Angina patients controlled on Nifedipine capsules alone or in combination with other antianginal medications may be safely switched to Nifedilong Prolonged Release tablets at the nearest, equivalent total daily dose (e.g. 1 Nifedipine capsule of 10 mg t.i.d. up to q.i.d. may be changed to 30 mg once daily of Nifedilong Prolonged Release tablet). Subsequent titration to higher doses may be necessary and should be initiated as clinically warranted. Experience with doses greater than 90 mg in patients with angina is limited. Therefore, doses greater than 90 mg should be used with caution and only when clinically warranted. No "rebound effect" has been observed upon discontinuation of Nifedilong read_full_document